PDS Biotech Reports Third Quarter 2026 Financial Results

On November 13, 2026 PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and clinical programs update and reported financial results for the quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program," said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. "We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated. We are pleased to have the support of Dr. Soon-Shiong and NantWorks, who share our belief in the promise of our immunotherapy platforms and led our PIPE financing of up to $22.3 million, the initial closing of which we completed this quarter."

Clinical and Corporate Update

•
Announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC with additional participation from current investors.

o
The PIPE includes a contingent milestone closing triggered by the Company’s submission to the FDA of a registrational Phase 3 clinical trial protocol for PDS0301 designed in collaboration with NantWorks, subject to the satisfaction or waiver of applicable closing conditions.

o
In connection with the PIPE, the Company entered into an option agreement granting NantWorks, LLC a one-year exclusive right to negotiate an exclusive license for the PDS0101 program.

o
Dr. Patrick Soon-Shiong, founder of NantWorks, and James Banaag appointed to the Company’s Board of Directors as Nant Capital designees.

•
Appointed three pharma veterans to the Company’s Board of Directors, effective October 18, 2026:

o
John Dawson CBE, Deborah Ramsdell, and Bruce Wendel bring deep corporate development, commercialization, and regulatory expertise to the Company.

•
Hosted a Key Opinion Leader (KOL) event discussing PDS0301 Phase 2 trials and projected clinical progress.

o
The event featured Jonathan M. Hernandez, M.D., an investigator with the Surgical Oncology Program at the National Cancer Institute’s Center for Cancer Research. Dr. Hernandez joined company management to discuss clinical outcomes from PDS0301 in the treatment of advanced liver-associated cancers, with a focus on the metastatic colorectal cancer (mCRC) cohort.

o
A replay of the event is available here.

•
Announced publication of VERSATILE-002 Phase 2 clinical trial results of PDS0101 with pembrolizumab in HPV16-positive recurrent and/or metastatic (R/M) head and neck cancer in JAMA Oncology.

•
Received issuance of a Japanese patent, JP Patent No.7909860, titled Methods and Compositions Comprising Cationic Lipids for Stimulating Type I Interferon Genes. The patent broadly covers compositions and use of the Versamune technology platform broadly for use as a T cell activating immunotherapy. A related US patent, US Patent No. 12,551,460, issued earlier in 2026.

•
Received issuance of patents titled HPV16 Non-HLA Restricted T Cell vaccines, Compositions and Methods of Use Thereof in both India and Israel, IN Patent No. 603830 and IL Patent No. 265833. The patents cover the composition and use of PDS0101 being developed to treat HPV16-positive cancers. A related US patent, US Patent No. 11,401,306, issued in 2022.

Third Quarter 2026 Financial Results

The Company’s cash and cash equivalents as of September 30, 2026 were $15.2 million.

Reported net loss was $7.6 million, or $0.11 per basic and diluted share, for the three months ended September 30, 2026, compared to $9.0 million, or $0.19 per basic and diluted share, for the three months ended September 30, 2025.

Research and development expenses were $2.1 million for the three months ended September 30, 2026, compared to $4.6 million for the three months ended September 30, 2025. The decrease of $2.5 million was primarily attributable to decreases of $1.6 million in clinical trial costs, $0.6 million in personnel costs and $0.3 million in manufacturing costs.

General and administrative expenses increased to $3.8 million for the three months ended September 30, 2026 from $3.6 million for the three months ended September 30, 2025. The increase of $0.2 million was primarily attributable to an increase of $0.3 million in professional fees, an increase of $0.1 million in personnel costs offset by a decrease of $0.2 million in stock based compensation costs.

Total operating expenses were $5.9 million for the three months ended September 30, 2026, compared to $8.1 million for the three months ended September 30, 2025.

Net interest expenses were $1.7 million for the three months ended September 30, 2026, compared to $0.9 million for the three months ended September 30, 2025.

(Press release, PDS Biotechnology, NOV 13, 2026, View Source [SID1234674751])

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

On November 13, 2026 Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, reported positive clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and a subset of patients with cutaneous neurofibromas (cNF) (Study PAS-004-103, NCT06961565), presented at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Cutaneous neurofibromas do not regress spontaneously and generally increase in number and size with age. The substantial reductions in cNF size reported today represent an encouraging clinical signal in a condition for which there are currently no FDA-approved systemic treatments," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "Importantly, these reductions have continued to deepen with longer treatment, including at the lowest doses tested. With our IND now cleared by FDA’s Division of Dermatology and Dentistry, these findings reinforce our confidence in the 4mg to 12mg dose range planned for Phase 2 and support advancing PAS-004 into a randomized, placebo-controlled study in cNF."

"The reductions in cNF size observed with oral PAS-004 highlight its potential to provide broad, visible improvements for patients through a systemic treatment approach, rather than relying on local procedures that can treat individual lesions," said Dr. Kartik Krishnan, Chief Medical Officer of Pasithea. "We are also seeing early activity in plexiform neurofibromas, with reductions in tumor volume across all dose levels and two participants meeting the REiNS threshold for partial response, including one at the first on-treatment MRI. Together with the favorable tolerability observed to date and a pharmacokinetic profile characterized by a 40-to-60-hour half-life and limited peak-to-trough fluctuations, these findings support the continued development of PAS-004 as a once-daily oral therapy for long-term treatment of NF1-associated neurofibromas."

Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the PAS-004 clinical data presented at the 2026 European Neurofibromatosis Conference. The webcast will be accessible here and through the Investors section of the Company’s website.

Study Overview

Study PAS-004-103 is an ongoing multicenter, open-label Phase 1/1b trial in adults with NF1 and symptomatic and inoperable, incompletely resected, or recurrent PN at five sites in the United States, Australia and South Korea. The study also evaluates up to 7 cNFs in participants with measurable lesions. Part A studies six escalating doses using a 3+3 design to select two doses for evaluation in Part B, a randomized dose expansion phase. The study also assesses safety, tolerability, pharmacokinetics and pharmacodynamics.

As of September 15, 2026, 19 participants have been enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg). Of these, 15 were evaluable for cNF and 18 for PN response. Median treatment duration ranged from 14.4 months at 4mg to approximately 4 months at 15mg and 24mg. One participant discontinued by sponsor decision for noncompliance, unrelated to safety.

Cutaneous Neurofibroma (cNF) Data

Fifteen participants were evaluable for cNF, with 71 target cNFs measured at baseline. Length and width of each target cNF were measured in triplicate with digital calipers. As there is no regulatory standard for assessing cNFs, both surface area (calculated from length and width) and longest diameter (the REiNS-recommended caliper measure) are reported.

Substantial Reductions in cNF Surface Area (Figure 1)

Reductions Across All Doses: All 15 evaluable participants showed reductions in summed target cNF surface area at best response, with a median best reduction of 41%.

Activity at Planned Phase 2 Doses: Among eight evaluable participants treated at 4, 8 and 12mg, the median best reduction was 46%. All six participants treated at 4mg and 8mg achieved reductions greater than 40%.

Safety and Tolerability

No treatment-related serious adverse events, discontinuations, adverse events of decreased LVEF, or cases of retinopathy have been reported. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). The two Grade 3 treatment-related events were asymptomatic increases in blood creatine phosphokinase (CPK), both of which resolved following a one-week dose interruption, with both participants continuing treatment. At the 4 to 12mg doses planned for Phase 2, dermatitis acneiform (rash) and diarrhea occurred in 33% and 11% of participants, respectively (data cut-off: September 15, 2026).

Pharmacokinetics

PAS-004 showed approximately dose-proportional exposure across the 4 to 24mg range, a terminal half-life of 40 to 60 hours, and limited peak-to-trough fluctuations (Cmax/Cmin of 1.5 to 2.0), consistent with findings from the Company’s ongoing Phase 1 study in advanced solid tumors and supporting once-daily dosing (data cut-off: October 7, 2026).

Next Steps

The FDA’s Division of Dermatology and Dentistry has cleared the IND for Study PAS-004-201, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cNF.

The ongoing Phase 1/1b study (PAS-004-103) will continue participant follow-up and advance toward Part B, a randomized two-dose expansion phase. The Company expects to complete pharmacodynamic analyses of resected cNFs in 2027 and present additional clinical data at future scientific meetings.

About Cutaneous Neurofibromas (cNF)

NF1-associated cutaneous neurofibromas (cNFs) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1. It is a serious condition and cNFs are associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNFs on an individual patient can range from a few to thousands. Although malignant transformation does not occur with NF1-associated cNF, cNFs are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA-approved systemic therapies for the treatment of NF1-associated cNF.

About Plexiform Neurofibromas (PN)

NF1-associated plexiform neurofibromas (PNs) are tumors originating from the nerve sheath that grow through and around nerves and may involve multiple nerve branches. Thirty to fifty percent (30-50%) of patients with NF1 will harbor PNs, which can undergo malignant transformation. PN-related morbidities, including pain, disfigurement and functional impairment are primarily caused by the direct impact of the tumor on surrounding structures and can be life-threatening when they compress vital organs or when they become malignant.

(Press release, Pasithea Therapeutics, NOV 13, 2026, View Source [SID1234674774])

Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism

On November 13, 2026 Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), reported positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5th data evaluation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia. To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants. To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose. Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion. As previously reported, one participant discontinued the study early and chose to enter home hospice care, and died one week later due to cancer progression. This participant has been classified as a non-responder for purposes of the primary endpoint. Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.

"We are thrilled with this outcome and what it means for individuals living with tumor hyperinsulinism," said Nevan Charles Elam, Founder and Chief Executive Officer of Rezolute. "Notably, these results substantially mirror the powerful outcomes that we have observed over the last few years in our expanded access program. We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027."

The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas). Ersodetug has been well-tolerated to date in the pivotal and extension phases of the study, with no drug-related safety findings attributed to ersodetug.

About upLIFT

The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI). Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care. Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension. The primary endpoint is the proportion of participants able to achieve at least a 50 percent reduction from baseline in GIR, a measure of intravenous glucose dependency for underlying hypoglycemia. Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.

About Tumor Hyperinsulinism

Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor. Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin. A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor. With high morbidity and mortality rates within tumor HI, there remains a significant unmet need for new therapies directed at hypoglycemia treatment. Ersodetug has shown real-world benefit in patients with insulinoma and NICTs.

About Ersodetug

Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia. Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia. Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.

(Press release, Rezolute, NOV 13, 2026, View Source [SID1234674752])

Molecular Partners to Present at Inaugural UBS Global Biopharma Conference

On November 13, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will present the Company’s latest developments and outlook at the Inaugural UBS Biopharma Conference, taking place 16–17 November 2026 in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chief Executive Officer Patrick Amstutz will present on Tuesday, November 17 at 8am GMT (9am CET) at the Rosewood Hotel in London.

A webcast will be accessible on the Molecular Partners website, under the Events tab.

(Press release, Molecular Partners, NOV 13, 2026, View Source [SID1234674775])

China’s First mRNA-Based In Vivo CAR-T Candidate! Medicilon Supports Regenelead RGL-208 IND Approval

On November 13, 2026 RGL-208 Injection, a dual-target in vivo CAR-T candidate independently developed by Regenelead, reported it has received implied clinical trial approval from the NMPA. It is intended for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. RGL-208 marks China’s first mRNA in vivo CAR-T product to enter clinical development, as well as Regenelead’s first in vivo CAR-T candidate advancing into the clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a partner of Regenelead, Medicilon provided pharmacokinetic and safety assessment studies for RGL-208, satisfying regulatory requirements for the NMPA, FDA and OECD, and enabling the candidate’s smooth transition into clinical testing.
Unmet Clinical Needs: Limitations of Current CAR-T Therapies
Conventional CAR-T therapies involve complex manufacturing and lengthy lead times, creating major barriers to patient access.
Relapsed/refractory B-cell hematological malignancies are highly heterogeneous and prone to recurrence, with poor outcomes for patients after multiple lines of treatment, representing a substantial unmet medical need. While several approved CAR-T products have offered curative potential, these existing therapies rely on ex vivo personalized manufacturing. The cumbersome workflows, long production cycles and high costs, paired with relapse risks driven by antigen loss and CAR-T cell exhaustion in single-target designs, severely limit accessibility. Expanding access so that more patients can rapidly receive CAR-T treatment remains one of the core challenges in cell therapy.
Dual-Target, Off-the-Shelf In Vivo CAR-T
Generating In Vivo CAR-T cells to advance cell therapy toward off-the-shelf solutions
RGL-208 Injection is a dual-target in vivo CAR-T candidate discovered and developed by Regenelead. As China’s first mRNA in vivo CAR-T product cleared for clinical investigation, it opens a new route to address key pain points of traditional CAR-T therapies and improve access to cell therapy.
mRNA-LNP delivery platform: mRNA encoding the CAR construct is specifically delivered to patients’ T cells to generate functional in vivo CAR-T cells, which recognize and eliminate tumor cells.

Dual-target design to mitigate relapse: By targeting two antigens simultaneously, RGL-208 helps reduce tumor escape caused by the loss or downregulation of a single antigen..

Off-the-shelf format without individualized manufacturing: Patients can be treated by a single intravenous administration — no leukapheresis, no waiting for in vitro manufacturing, drastically cutting waiting time.

Lower barriers for manufacturing and access: The mRNA-LNP platform offers the potential for standardized, large-scale manufacturing, which could reduce production costs and extend cutting-edge cell therapy to a broader patient population.

The IND approval of RGL-208 represents a landmark breakthrough for Regenelead in in vivo CAR-T research, placing the company among China’s front-runners for clinical translation of in vivo CAR-T programs. It further demonstrates the innovative strength and translational capacity of Regenelead’s proprietary technology platforms.

Platform-Driven Preclinical Support

Medicilon’s CGT platform powers preclinical development for cell and gene therapies

During RGL-208’s preclinical development, Medicilon deployed a suite of analytical platforms including flow cytometry, ELISA, PCR and LC-MS/MS to conduct systematic in vivo efficacy and toxicity evaluations. For the cynomolgus monkey toxicology program tailored to RGL-208, our team established immune-related response monitoring and emergency-response plans tailored to the product’s characteristics. In pharmacology studies using humanized immunodeficient mouse models, Medicilon precisely constructed the animal models and carefully controlled for model-related background lesions during data interpretation, delivering a scientifically rigorous and complete assessment of RGL-208’s efficacy and safety.

(Press release, Shanghai Medicilon, NOV 13, 2026, View Source [SID1234674753])